免疫疗法
肿瘤微环境
癌症治疗
免疫系统
癌症免疫疗法
医学
癌症
免疫检查点
癌症研究
癌症治疗
抗原呈递
药物输送
细胞疗法
T细胞
PD-L1
嵌合抗原受体
光动力疗法
免疫学
靶向治疗
癌细胞
放射治疗
联合疗法
免疫监视
计算生物学
作者
Linxi Wang,Fei Li,Zhaoyan Zhao,Minggao Zhao,Lanxin Luo
标识
DOI:10.1016/j.mtbio.2026.103379
摘要
Cancer immunotherapy has emerged as a new paradigm for the treatment of malignant tumors, demonstrating significant potential for clinical translation. Although notable breakthroughs have been achieved with approaches such as immune checkpoint inhibitors (ICIs) and cell-based therapies, several major challenges remain. Specifically, treatment-related toxicities, tumor immune escape mechanisms (e.g., impaired antigen presentation and T cell dysfunction), and the immunosuppressive nature of the tumor microenvironment (TME) remain major challenges. To address these limitations, metal-organic frameworks (MOFs) have provided an innovative platform for developing next-generation immune delivery systems, owing to their tunable structural design, high drug loading and controlled release capabilities, and immunomodulatory properties. This review systematically elaborates on the advantages of MOFs as nanodrug delivery systems (NDDS), including high payload capacity, targeting ability, and biosafety. It further extends to their innovative applications in the co-delivery of immunomodulatory agents, such as the synergistic delivery of ICIs and tumor antigens. Beyond these foundational aspects, it also covers MOF-based combination therapy strategies, which specifically involve spatiotemporal synergy with chemodynamic therapy (CDT) and photodynamic therapy (PDT), while simultaneously addressing the challenges and future directions associated with their clinical translation. Notably, the review places special emphasis on the fact that MOFs can significantly enhance therapeutic efficacy through key mechanisms, including the induction of immunogenic cell death (ICD) and the remodeling of the immune microenvironment. Looking ahead, with the deepening integration of materials science and tumor immunology, MOFs are well-positioned to drive advancements in the development of cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI